EMA positive opinion for ViiV’s cabotegravir
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals
Read More
Tag: cabotegravir
ViiV’s cabotegravir scores breakthrough designation for HIV prevention
Designation is based on results from phase IIb/III HPTN 083 trial
Read More
ViiV’s long-acting HIV drug beats standard of care in prevention study
Study was ended early after drug hit primary endpoint
Read More
ViiV HIV prevention trial stopped early on efficacy
ViiV said cabotegravir was found to be 69% more effective at preventing HIV acquisition than daily oral PrEP with emtricitabine/tenofovir disoproxil (FTC/TDF)
Read More
ViiV’s HIV regimen hit with setback in the US
US regulators have declined ViiV Healthcare’s application to market an investigational long-acting regimen for the treatment of HIV
Read More
GSK HIV combo meets main goal in Phase III study
The drug could now be administered every eight weeks compared to every four.
Read More
ViiV submits regulatory application to EMA for investigational HIV combo
The application is for cabotegravir and Edurant (rilpivirine) as the first monthly, injectable treatment for HIV.
Read More
ViiV submits NDA for first long-acting, injectable HIV combo
The combination of cabotegravir and Edurant has the potential to give people living with HIV one month between doses.
Read More
Encouraging data for ViiV’s long-acting, two-drug HIV therapy
ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV.
Read More
ViiV, Janssen’s two-drug HIV regimen hits PhIII targets
ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.
Read More
ViiV trials drug for HIV prevention in women
ViiV Healthcare has initiated a Phase III study exploring the efficacy of long-acting cabotegravir for the prevention of HIV infection in sexually active women.
Read More
ViiV trials long-acting, two-drug HIV regimen
ViiV Healthcare has kicked off a late-stage study testing a long-acting, two-drug regimen of its cabotegravir and Janssen’s rilpivirine in virally suppressed adults with HIV-1 infection
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
